Candel Therapeutics Inc. Common Stock CADL · Stock Open Candel Therapeutics Inc. Common Stock in new tab
Candel Therapeutics Inc. Common Stock Analysis (CADL)
Is Candel Therapeutics Inc. Common Stock a good investment? Candel Therapeutics Inc. Common Stock (CADL) is currently trading at 10.16 USD. Market analysts have a consensus price target of 21.75 USD. This suggests a potential upside from current levels.
Earnings Schedule: Candel Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -0.63.
Investor FAQ
Does Candel Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Candel Therapeutics Inc. Common Stock?
Candel Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.49.
Company Profile
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Community Discussion